Published in Vaccine on February 20, 2008
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 1.12
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A (2010) 0.96
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines. Cancer Immunol Immunother (2012) 0.89
Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer (2013) 0.88
Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Res (2012) 0.84
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J Immunol (2009) 0.82
Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor. J Biol Chem (2013) 0.81
Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model. J Immunol (2016) 0.80
Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol (2011) 0.78
CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany. Hum Vaccin Immunother (2013) 0.75
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Sequence analysis of peptides bound to MHC class II molecules. Nature (1991) 5.99
Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol (2005) 5.83
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 4.16
Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity (1998) 4.15
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Cancer vaccines: between the idea and the reality. Nat Rev Immunol (2003) 3.24
Identification of ecotropic proviral sequences in inbred mouse strains with a cloned subgenomic DNA fragment. Proc Natl Acad Sci U S A (1980) 3.19
T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol (2001) 2.51
A decade of AIRE. Nat Rev Immunol (2007) 2.45
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007) 2.38
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol (1987) 2.06
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell (1997) 1.80
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Clonal competition inhibits the proliferation and differentiation of adoptively transferred TCR transgenic CD4 T cells in response to infection. J Immunol (2006) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med (2007) 1.68
A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res (2002) 1.51
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48
Molecular and biological characterization of the endogenous ecotropic provirus of BALB/c mice. J Virol (1985) 1.45
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. J Virol (1997) 1.37
Endogenous mouse leukemia viruses. Annu Rev Genet (1983) 1.30
CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A (2001) 1.22
Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int Immunol (2001) 1.17
Genetic interactions in the spontaneous production of endogenous murine leukemia virus in low leukemic mouse strains. J Exp Med (1982) 1.13
The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother (2000) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Immunization against endogenous retroviral tumor-associated antigens. Cancer Res (2001) 1.05
Germ line integration of a murine leukemia provirus into a retroviruslike sequence. J Virol (1987) 1.02
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection. J Immunol (1992) 0.98
Potential target antigens for immunotherapy in human pancreatic cancer. Cancer Lett (2007) 0.90
Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res (2007) 0.90
In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest (1998) 0.89
Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur J Immunol (2000) 0.88
An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J Immunol (2001) 0.83
Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation. Int J Cancer (2004) 0.80
SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma. Cancer Gene Ther (2000) 0.76